Description
Troxerutin-Acos Pharmacodynamics
Troxerutin selectively accumulates in the endothelial layer of blood vessels, penetrates deep into the subendothelial layer of the venous wall, creating higher concentrations there than in the surrounding tissues. It prevents damage to cell membranes caused by oxidative reactions. Antioxidant effect is manifested by prevention and elimination of oxidative properties of oxygen, suppression of lipid oxidation and protection of vascular endothelium from oxidative effects of hydroxyl radicals. Troxerutin reduces the increased permeability of capillaries and has venotonic effect. The cytoprotective effect results from inhibition of activation and adhesion of neutrophils, reduction of erythrocyte aggregation and increase of their resistance to deformation, reduction of release of inflammatory mediators.
Troxerutin increases veno-arterial reflux and increases the repletion time of the veins, improves microcirculation and microvascular perfusion.
Troxerutin reduces pathological changes associated with venous insufficiency: edema, pain, improves tissue trophism.
Due to its influence on permeability and resistance of capillary walls troxerutin helps to slow down the progression of diabetic retinopathy.
The effect of troxerutin on the rheological properties of blood helps to prevent the development of retinal vascular microthrombosis.
Indications
-chronic venous insufficiency;
-postthrombotic syndrome;
-trophic disorders in varicose veins and trophic ulcers;
-as an adjunctive treatment after sclerotherapy of veins and removal of varicose veins;
-Hemorrhoids (pain, exudation, itching and bleeding);
-as an adjunctive treatment for retinopathy in patients with diabetes mellitus, arterial hypertension and atherosclerosis.
Contraindications
-High sensitivity to rutoside or other components of the drug;
-pregnancy (first trimester);
-ulcer disease of the stomach and duodenum;
-Chronic gastritis in the acute phase;
-Children under 18 years of age (the experience of clinical use is insufficient);
Period of breast-feeding.
With caution
In patients with chronic renal insufficiency (with long-term use);
-In pregnancy (II and III trimesters).
Dosage and administration.
- Inside, with a meal. The capsules should be swallowed whole with plenty of fluid.
- In chronic venous insufficiency and its complications, symptomatic treatment of hemorrhoids in the initial phase of treatment is prescribed 1 capsule (300 mg) 2-3 times a day (600-900 mg), depending on the severity of symptoms. The effect usually develops within 2 weeks. Treatment is discontinued after symptoms and edema have disappeared.
- If symptoms recur, treatment is resumed in the same dose or the dose is reduced to 1 capsule 2 times a day (600 mg).
- The achieved effect is maintained for at least 4 weeks.
- The course of treatment is an average of 3-4 weeks.
- It is used in diabetic retinopathy in a dose of 1800-3000 mg in 6-10 capsules (2 times a day in 3-5 capsules (1800-3000 mg)).
- The average course of treatment is 3-4 weeks.
- The need for longer treatment is determined after consultation with the doctor and individually.
